Global ALK Inhibitors Market Analysis 2019

Tutorials Get 15% Discount on First Report

The Global ALK Inhibitors Market is poised to grow at a CAGR of around 19% over the next decade during 2018 to 2026. Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase (RTK) belonging to the insulin receptor (IR) superfamily. ALK, also known as CD246 is encoded by the ALK gene in humans. Immunohistochemical analysis of adult human tissues uncovers that ALK expression is sparsely scattered in neural cells, endothelial cells and pericytes in the brain.

Factors such as high incidence rates of diseases like lung cancer, increasing drug approvals, and advances in therapeutics are driving the market growth. Though, the side effects associated with the treatment restrain the market growth. Moreover, patient assistance programs and high efficacy of ALK inhibitors in the treatment are opportunities for the ALK inhibitors market.

Based on type, the third-generation anaplastic lymphoma kinase inhibitors segment is going to have a lucrative growth during the forecast period, owing to the good response rates seen in patients with varying treatment history.

The key vendors mentioned are F. Hoffmann-La Roche Ltd, Pfizer Inc, Delenex Therapeutics, Novartis AG, Astellas, Takeda Pharmaceutical Co Ltd, Amgen, Tesaro, Teva, and AstraZeneca.

Types Covered:
• First-generation Anaplastic Lymphoma Kinase Inhibitors
• Second-generation Anaplastic Lymphoma Kinase Inhibitors
• Third-generation Anaplastic Lymphoma Kinase Inhibitors

Distribution Channels Covered:
• Online Distribution Channel
• Offline Distribution Channel

Regions Covered:
• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Key Questions Answered in this Report:
• How this market evolved since the year 2016
• Market size estimations, forecasts and CAGR for all the segments presented in the scope
• Key Market Developments and financials of the key players
• Opportunity Analysis for the new entrants
• SWOT Analysis of the key players
• Fastest growing markets analysed during the forecast period

Your Name:
Your Phone:
Company Name:
Country:
Your Email:
Description:

1 Market Synopsis

2 Research Outline
2.1 Research Snapshot
2.2 Research Methodology
2.3 Research Sources
2.3.1 Primary Research Sources
2.3.2 Secondary Research Sources

3 Market Dynamics
3.1 Drivers
3.2 Restraints

4 Market Environment
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global ALK Inhibitors Market, By Type
5.1 Introduction
5.2 First-generation Anaplastic Lymphoma Kinase Inhibitors
5.3 Second-generation Anaplastic Lymphoma Kinase Inhibitors
5.4 Third-generation Anaplastic Lymphoma Kinase Inhibitors

6 Global ALK Inhibitors Market, By Distribution Channel
6.1 Introduction
6.2 Online Distribution Channel
6.3 Offline Distribution Channel

7 Global ALK Inhibitors Market, By Geography
7.1 North America
7.2 Europe
7.3 Asia Pacific
7.4 South America
7.5 Middle East & Africa

8 Strategic Benchmarking

9 Vendors Landscape
9.1 F. Hoffmann-La Roche Ltd.
9.2 Pfizer Inc.
9.3 Delenex Therapeutics
9.4 Novartis AG
9.5 Astellas
9.6 Takeda Pharmaceutical Co. Ltd.
9.7 Amgen
9.8 Tesaro
9.9 Teva
9.10 AstraZeneca

List of Data Tables
1 Global ALK Inhibitors Market Outlook, By Region (2016-2026) ($MN)
2 Global ALK Inhibitors Market Outlook, By Type (2016-2026) ($MN)
3 Global ALK Inhibitors Market Outlook, By First-generation Anaplastic Lymphoma Kinase inhibitors (2016-2026) ($MN)
4 Global ALK Inhibitors Market Outlook, By Second-generation Anaplastic Lymphoma Kinase inhibitors (2016-2026) ($MN)
5 Global ALK Inhibitors Market Outlook, By Third-generation Anaplastic Lymphoma Kinase inhibitors (2016-2026) ($MN)
6 Global ALK Inhibitors Market Outlook, By Distribution Channel (2016-2026) ($MN)
7 Global ALK Inhibitors Market Outlook, By Online Distribution Channel (2016-2026) ($MN)
8 Global ALK Inhibitors Market Outlook, By Offline Distribution Channel (2016-2026) ($MN)
9 North America ALK Inhibitors Market Outlook, By Country (2016-2026) ($MN)
10 North America ALK Inhibitors Market Outlook, By Type (2016-2026) ($MN)
11 North America ALK Inhibitors Market Outlook, By Distribution Channel (2016-2026) ($MN)
12 Europe ALK Inhibitors Market Outlook, By Country (2016-2026) ($MN)
13 Europe ALK Inhibitors Market Outlook, By Type (2016-2026) ($MN)
14 Europe ALK Inhibitors Market Outlook, By Distribution Channel (2016-2026) ($MN)
15 Asia Pacific ALK Inhibitors Market Outlook, By Country (2016-2026) ($MN)
16 Asia Pacific ALK Inhibitors Market Outlook, By Type (2016-2026) ($MN)
17 Asia Pacific ALK Inhibitors Market Outlook, By Distribution Channel (2016-2026) ($MN)
18 South America ALK Inhibitors Market Outlook, By Country (2016-2026) ($MN)
19 South America ALK Inhibitors Market Outlook, By Type (2016-2026) ($MN)
20 South America ALK Inhibitors Market Outlook, By Distribution Channel (2016-2026) ($MN)
21 Middle East & Africa ALK Inhibitors Market Outlook, By Country (2016-2026) ($MN)
22 Middle East & Africa ALK Inhibitors Market Outlook, By Type (2016-2026) ($MN)
23 Middle East & Africa ALK Inhibitors Market Outlook, By Distribution Channel (2016-2026) ($MN)

Your Name:
Your Phone:
Company Name:
Country:
Your Email:
Description:

Related Reports

Global Patient Engagement Solutions Market Analysis 2020

Dec, 2020

Patient engagement solutions allow management of the healthcare information and provide access to healthcare professionals to interact with the patients....

Global Telehealth Market Analysis 2020

Dec, 2020

Telehealth is the use of digital information and communication technologies to access advanced healthcare care and manage it accordingly and...

Global Healthcare Cloud Computing Market Analysis 2020

Dec, 2020

Cloud computing can be defined as the practice of using remote servers in place of a local server or network,...

Global Healthcare IT Integration Market Analysis 2020

Dec, 2020

Healthcare IT integration can be defined as a type of medical devices category through which the physicians and doctors can...